Physician profile
Stephen P Meyer
NPI 1083672125
$366.74
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2021: $11.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $48.61 | 2019 | |
| Lilly USA, LLC | $43.96 | 2019 | |
| Novo Nordisk INC | $43.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.32 | 2019 | |
| Bausch Health US, LLC | $23.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.26 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.85 | 2019 | |
| Pfizer INC. | $15.41 | 2019 | |
| Orexo US, INC. | $11.52 | 2021 | |
| Merck Sharp & Dohme LLC | $11.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.